Cortexyme Inc (NASDAQ:CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
- The SAD trial was designed to evaluate the safety and pharmacokinetics of COR588 in healthy volunteers.
- In the SAD portion of the Phase 1 trial, preliminary results indicate COR588 was well-tolerated across all four cohorts in the dose range from 25 mg to 200 mg with no serious adverse events.
- No clinically significant findings were observed on other safety measures, including vital signs, laboratory findings, telemetry, or ECGs.
- Related: Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND.
- COR588 exhibited an 11-to-12-hour half-life consistent with once-daily dosing and a dose-proportional pharmacokinetic profile.
- The Company will share the complete data set from the COR588 Phase 1 trial in Q2 of 2022 once the multiple ascending dosing phase is complete.
- Price Action: CRTX shares are up 7.76% at $4.58 during the market session on the last check Tuesday.
